In vivo model systems in P-glycoprotein-mediated multidrug resistance

Critical Reviews in Clinical Laboratory Sciences

Volumn 35, Issue 1, 1998, Pages 1-57

  Van De Vrie, Wim ^a,b   Marquet, Richard L ^b   Stoter, Gerrit ^a   De Bruijn, Ernst A ^c   Eggermont, Alexander M M ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chemosensitizer; In vivo; Modulation of MDR; Multidrug resistance (MDR); P glycoprotein; Review

Indexed keywords

1,4 DIHYDRO 4 (2 ISOPROPYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID [2 (N BENZYL N METHYLAMINO)ETHYL] METHYL ESTER; 3' DEAMINO 2' FLUORO 3' HYDROXYDOXORUBICIN 14 PIMELATE; ANTINEOPLASTIC AGENT; CHEMOSENSITIZER; COLCHICINE; CYCLOSPORIN A; DEXNIGULDIPINE; DEXVERAPAMIL; DIGOXIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; NIFEDIPINE; PACLITAXEL; PAK 200; PROTEIN KINASE C INHIBITOR; SDZ 280446; STEROID; TRIFLUOPERAZINE; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; XENOBIOTIC AGENT;

ASCITES TUMOR; BONE MARROW; CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CELL MEMBRANE TRANSPORT; CYTOTOXICITY TEST; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOXICITY; DRUG TRANSPORT; GENETIC TRANSFECTION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; LEUKEMIA CELL; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN;

MURINAE; MUS MUSCULUS; RODENTIA; VINCA;

EID: 0031977227     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408369891234165     Document Type: Review

References (235)

1. Chin K-V, Pastan I Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993; 60: 157-80.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
3. Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem 1994; 31: 1-61.
4. van der Heyden S, Gheuens E, De Bruijn E, et al. P-glycoprotein: clinical significance and methods of analysis. Crit Rev Clin Lab Sci 1995; 32: 221-64.
5. Broxterman HJ, Lankelma J Pinedo HM. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996; 32A: 1024-33.
6. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-20.
7. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
8. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
9. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-4.
10. Ro J, Sahin A, Ro JY, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21: 787-91.
11. Bourhis J, Goldstein LJ, Riou G, et al. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 1989; 49: 5062-5.
12. Goldstein LJ, Fojo AT, Ueda K, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990; 8: 128-36.
13. Chan HSL, DeBoer G, Haddad G, et al. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 1995; 9: 275-318.
14. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 32A: 1039-50.
15. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991 ; 83: 708-12.
16. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-6.
17. Sato H, Gottesman MM, Goldstein LJ, et al. Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 1990; 14: 11-22.
18. Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17-24.
19. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-5.
20. Licht T, Pastan I, Gottesman M, et al. P-Glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 1994; 69: 159-71.
21. Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res 1994; 18: 233-43.
22. Chan HSL, Thorner PS, Haddad G, et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689-704.
23. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608-14.
24. Zhou DC, Marie JP, Suberville AM, et al. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879-85.
25. Holmes JA, West RR. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 1994; 69: 382-4.
26. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
27. Juranka PF, Zastawny RL Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583-92.
28. Croop JM. P-glycoprotein structure and evolutionary homologies. Cytotechnology 1993; 12: 1-32.
29. Buschman E, Lepage P Gros P. P-glycoprotein homologues. Cancer Treat Res 1994; 73: 17-39.
30. Shen D-x, Fojo A, Roninson IB, et al. Multidrug resistance in DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol 1986; 6: 4039-45.
31. Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-8.
32. Van der Bliek AM, Kooiman PM, Schneider C, et al. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1988; 71: 401-11.
33. Gros P, Croop J Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986; 47: 371-80.
34. Gros P, Raymond M, Bell J, et al. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 1988; 8: 2770-8.
35. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Moll Cell Biol 1990; 10: 1652-63.
36. Deuchars KL, Duthie M Ling V. Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1992; 1130: 157-65.
37. Endicott JA, Sarangi F Ling V. Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq 1991; 2: 89-101.
38. Childs S, Ling V. Duplication and evolution of the P-glycoprotein genes in pig. Biochim Biophys Acta 1996; 1307: 205-12.
39. Silverman JA, Raunio H, Gant TW, et al. Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 1991; 106: 229-36.
40. Smit JJM, Schinkel AH, Mol CAAM, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994; 71: 638-39.
41. Ng WF, Sarangi F, Zastawny RL, et al. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989; 9: 1224-32.
42. Hsu SI-H, Lothstein L Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 1989; 264: 12053-62.
43. 1 transcripts in multidrug-resistant Chinese hamster lung cells. J Biol Chem 1991; 266: 4545-55.
44. Arceci RJ, Croop JM, Horwitz SB, et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350-4.
45. Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346-50.
46. Teeter LD, Becker FF, Chisari FV, et al. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990; 10: 5728-35.
47. Schinkel AH, Mol CAAM, Wagenaar E, et al. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995; 31A: 1295-8.
48. Baas F, Borst P. The tissue dependent expression of hamster P-glycoprotein genes. FEBS Lett 1988; 229: 329-32.
49. Bradley G, Georges E, Ling V. Sex-dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol 1990; 145: 398-408.
50. Chin JE, Soffir R, Noonan KE, et al. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-20.
51. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 1992; 80: 2729-34.
52. Brown PC, Thorgeirsson SS Silverman JA. Cloning and regulation of the rat mdr2 gene. Nucl Acids Res 1993; 21: 3885-91.
53. Furuya KN, Gebhart R, Schuetz EG, et al. Isolation of rat pgp3 cDNA: evidence for gender and zonal regulation of expression in the liver. Biochim Biophys Acta 1994; 1219: 636-44.
54. Buschman E, Arceci RJ, Croop JM, et al. mdr2 Encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 1992; 267: 18093-9.
55. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
56. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-87.
57. Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-64.
58. Georges E, Bradley G, Gariepy J, et al. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 152-6.
59. Cordon-Cardo C, O'Brien JP, Casals D, et al. Mulidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-8.
60. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
61. Chin KV, Chauhan SS, Pastan I, et al. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990; 1: 361-5.
62. Teeter LD, Estes M, Chan JV, et al. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog 1993; 8: 67-73.
63. Hill BA, Brown PC, Preisegger K-H, et al. Regulation of mdr1b gene expression in Fischer, Wistar and Sprague-Dawley rats in vivo and in vitro. Carcinogenesis 1996; 17: 451-7.
64. Jetté L, Beaulieu E, Leclerc J-M, et al. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996; 270: F756-65.
65. Borst P, Schinkel AH, Smit JJM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993; 60: 289-99.
66. Dutt A, Heath LA, Nelson JA. P-glycoprotein and organic cation secretion by the mammalian kidney. J Pharmacol Exp Ther 1994; 269: 1254-60.
67. Speeg KV, Maldonado AL, Liaci J, et al. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther 1992; 261: 50-5.
68. Speeg KV, Maldonado AL. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchinine and doxorubincin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 1994; 34: 133-6.
69. De Lannoy IAM, Mandin RS Silverman M. Renal secretion of vinblastine, vincristine and colchicine in vivo. J Pharmacol Exp Ther 1994; 268: 388-95.
70. Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992; 102: 879-85.
71. Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmacol Res 1995; 12: 1304-10.
72. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028-33.
73. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-5.
74. Kamimoto Y, Gatmaitan Z, Hsu J, et al. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989; 264: 11693-8.
75. Schrenk D, Gant TW, Preisegger K-H, et al. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 1993; 17: 854-60.
76. Speeg KV, Maldonado AL. Effect of cyclosporine on colchincine partitioning in the rat liver. Cancer Chemother Pharmacol 1993; 32: 434-6.
77. Tatsuta T, Naito M, Oh-hara T, et al. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383-91.
78. Barrand MA, Robertson KJ von Weikersthal SF. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 1995; 374: 179-83.
79. Didier AD, Loor F. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer 1995; 63: 263-7.
80. Wang Q, Yang H, Miller DW, et al. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 1995; 211: 719-26.
81. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248-52.
82. van Kalken CK, Broxterman HJ, Pinedo HM, et al. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67: 284-9.
83. Yang C-PH, Cohen D, Greenberger LM, et al. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 1990; 265: 10282-8.
84. Arceci RJ, Baas F, Raponi R, et al. Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus. Mol Reprod Dev 1990; 25: 101-9.
85. Chin KV, Chauhan SS, Abraham I, et al. Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. J Cell Physiol 1992; 152: 87-94.
86. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-705.
87. Valverde MA, Bond TD, Hardy SP, et al. The multidrug resistance P-glycoprotein modulates cell regulatory volume decrease. EMBO J 1996; 15: 4460-8.
88. De Greef C, van der Heyden S, Viana F, et al. Lack of correlation between mdr-1 expression and volume-activation of chloride-currents in rat colon cancer cells. Pflugers Arch 1995; 430: 296-8.
89. Schinkel AH, Roelofs MEM Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991; 51: 2628-35.
90. Smit JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-62.
91. Borst P, Schinkel AH. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 1996; 32A: 985-90.
92. Oude Elferink RPJ, Groen AK. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 1995; 23: 617-25.
93. Gros P, Ben Neriah YB, Croop JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728-31.
94. Raymond M, Rose E, Housman DE, et al. Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol Cell Biol 1990; 10: 1642-51.
95. Schott B, Bennis S, Pourquier P, et al. Differential over-expression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine. Int J Cancer 1993; 55: 115-21.
96. Barrand MA, Twentyman PR. Differential recognition of mdr1 a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies. Br J Cancer 1992; 65: 239-45.
97. Lothstein L, Hsu SI-H, Horwitz SB, et al. Alternate overexpression of two phosphoglycoprotein genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem 1989; 264: 16054-8.
98. Ganapathi R, Kuo T, Teeter L, et al. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol 1991; 39: 1-8.
99. Kajiji S, Talbot F, Grizzuti K, et al. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry 1993; 32: 4185-94.
100. Tang-Wai DF, Kajiji S, DiCapua F, et al. Human (MDR1) and mouse (mdr1,mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995; 34: 32-9.
101. 939/941. Biochemistry 1994; 33: 5041-8.
102. Devine SE, Melera PW. Diversity of multidrug resistance in mammalian cells. J Biol Chem 1994; 269: 6133-9.
103. Shen D-W, Cardarelli C, Hwang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986; 261: 7762-70.
104. Choi K, Chen C-j, Kriegler M, et al. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988; 53: 519-29.
105. Gros P, Dhir R, Croop J, et al. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 1991; 88: 7289-93.
106. Foote SJ, Kyle DE, Martin RK, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990; 345: 255-8.
107. Cardarelli CO, Aksentijevich I, Pastan I, et al. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995; 55: 1086-91.
108. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995; 13: 475-9.
109. Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma. A relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892-8.
110. Keith WN, Mee PJ Brown R. Response of mouse skin tumors to doxorubicin is dependent on carcinogen exposure. Cancer Res 1990; 50: 6841-7.
111. Spoelstra EC, Dekker H, Schuurhuis GJ, et al. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 1991; 41: 349-59.
112. Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995; 34: 235-41.
113. Dong Z, Radinsky R, Fan D, et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994; 86: 913-20.
114. van de Vrie W, Gheuens EEO, Durante NMC, et al. In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 1993; 119: 609-14.
115. Iwahashi T, Okochi E, Ariyoshi K, et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993; 53: 5475-82.
116. Niwa K, Yamada K, Furukawa T, et al. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1- (2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to Adriamycin. Cancer Res 1992; 52: 3655-60.
117. Hitselberger Kanitz MH, Mastro JM, Moore RE, et al. In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids. Anticancer Res 1994; 14: 857-68.
118. Berlion M, Arvelo F, Leonce S, et al. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft. In Vivo 1993; 7: 399-405.
119. Ferrandis E, Da Silva J, Riou G, et al. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res 1994; 54: 2256-61.
120. rev. Jpn J Cancer Res 1993; 84: 1201-8.
121. Johnson RK, Chitnis MP, Embrey WM, et al. In vivo characteristics of resistance and cross-resistance of an Adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 1978; 62: 1535-47.
122. Shinoda H, Inaba M Tsuruo T. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52. Cancer Res 1989; 49: 1722-6.
123. Radel S, Fredericks W, Mayhew E, et al. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells. Cancer Chemother Pharmacol 1990; 25: 241-6.
124. Boesch D, Gavériaux C, Jachez B, et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-33.
125. Sato W, Fukazawa N, Suzuki T, et al. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 1991; 51: 2420-4.
126. Kühl JS, Sikic BI, Blume KG, et al. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol 1992; 20: 1048-54.
127. Shinoda H, Ebisu H, Mitsuhashi J, et al. Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model. Cancer Chemother Pharmacol 1992; 30: 355-40.
128. Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995; 35: 271-7.
129. Volm M, Bak M, Efferth T, et al. Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein. J Cancer Res Clin Oncol 1989; 115: 17-24.
130. Efferth T, Klett T, Mattern J, et al. Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo. Anticancer Res 1991; 11: 1275-80.
131. Wang L, Yang C-PH, Horwitz SB, et al. Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. Cancer Chemother Pharmacol 1994; 34: 96-102.
132. Watanabe T, Naito M, Kokubu N, et al. Regression of established tumors expressing P-glycoprotein by combinations of Adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 1997; 89: 512-8.
133. Satta T, Isobe K-i, Yamauchi M, et al. Establishment of drug resistance in human gastric and colon carcinoma xenograft lines. Jpn J Cancer Res 1991; 82: 593-8.
134. Mimnaugh EG, Fairchild CR, Fruehauf JP, et al. Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol 1991; 42: 391-402.
135. Leveille-Webster CR, Arias IA. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin Cancer Res 1996; 2: 695-706.
136. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-9.
137. Broxterman HJ, Feller N, Kuiper CM, et al. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts. Int J Cancer 1995; 61: 880-6.
138. Plumb JA, Wishart GC, Setanoians A, et al. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. Biochem Pharmacol 1994; 47: 257-66.
139. Zou Y, Ling YH, Van NT, et al. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 1994; 54: 1479-84.
140. 125I]MRK-16 monoclonal antibody. Nucl Med Biol 1995; 22: 497-504.
141. Hill AB, Beck WT, Trent JM. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line. Cancer Res 1988; 48: 393-8.
142. Bellamy WT, Odeleye A, Finley P, et al. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am J Pathol 1993; 142: 691-8.
143. Bellamy WT, Mendibles P, Bontje P, et al. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype. Cancer Chemother Pharmacol 1996; 37: 305-16.
144. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996; 56: 4332-7.
145. Colombo T, Gonzalez Paz O D'Incalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73: 866-71.
146. Schecter RL, Woo A, Duong M, et al. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res 1991; 51: 1434-42.
147. Miyamoto K-I, Wakabayashi D, Minamino T, et al. Characterization of naturally acquired multiple drug resistance of Yoshida rat ascites hepatoma AH66 cell line. Anticancer Res 1996; 16: 1235-40.
148. Yang J-M, Goldenberg S, Gottesmann MM, et al. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 1994; 54: 730-7.
149. Yang J-M, Hait WN. Use of multidrug resistant L1210 cell line for in vitro and in vivo drug screening. Proc Am Assoc Cancer Res 1991; 32: 364.
150. Keller RP, Altermatt HJ, Nooter K, et al. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992; 50: 593-7.
151. Christensen JG, LeBlanc GA. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 1996; 56: 574-81.
152. Pearson JW, Fogler WE, Volker K, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991; 83: 1386-91.
153. MDR1: ascites models of human breast cancer. Br J Cancer 1996; 73: 154-61.
154. Jansen WJM, Pinedo HM, Kuiper CM, et al. Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann Oncol 1994; 5: 733-9.
155. O'Conner R, Liu C, Ferris CA, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995; 86: 4286-94.
156. Liu C, Lambert JM, Teicher BA, et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 1996; 87: 3892-8.
157. Boven E, Winograd B, Berger DP, et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 1992; 52: 5940-7.
158. Biedler JL, Riehm H, Peterson RHF, et al. Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst 1975; 55: 671-80.
159. Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996; 56: 2434-9.
160. Serra M, Scotlandi K, Manara MC, et al. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993; 13: 323-30.
161. Bashir I, Sikora K, Abel P, et al. Establishment and in vivo characterization of multidrug-resistant Dunning R3327 rat prostate-carcinoma cell-lines. Int J Cancer 1994; 57: 719-26.
162. Fichtner I, Stein U, Hoffmann J, et al. Characterization of four drug-resistant P388 sublines: resistance/sensivity in vivo, resistance- and proliferation-markers, immunogenicity. Anticancer Res 1994; 14: 1995-2004.
163. Killion JJ, Radinsky R, Dong Z, et al. The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype. Cancer Immunol Immunother 1993; 36: 381-6.
164. Formelli F, Rossi C, Supino R, et al. In vivo characterization of a doxorubicin resistant B16 melanoma cell line. Br J Cancer 1986; 54: 223-33.
165. Ganapathi R, Grabowski D, Schmidt H, et al. Characterization in vitro and in vivo of progressively Adriamycin-resistant B16-BL6 mouse melanoma cells. Cancer Res 1987; 47: 3464-8.
166. Bradley G, Sharma R, Rajalakshmi S, et al. P-Glycoprotein expression during tumor progression in the rat liver. Cancer Res 1992; 52: 5154-61.
167. Gottesman MM, Mickisch GH, Pastan I. In vivo models of P-glycoprotein-mediated multidrug resistance. Cancer Treat Res 1994; 73: 107-28.
168. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 42-9.
169. Mattern J, Bak M, Hahn EW, et al. Human tumor xenografts as model for drug testing. Cancer Metas Rev 1988; 7: 263-84.
170. Fidler IJ. Role of the organ environment in the pathogenesis of cancer metastasis. Proc Am Assoc Cancer Res 1993; 34: 570.
171. Genne P, Dimanche-Boitrel MT, Mauvernay RY, et al. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 1992; 52: 2797-801.
172. Mehta BM, Rosa E, Biedler JL, et al. In vivo uptake of carbon-14-colchicine for identification of tumor multidrug resistance. J Nucl Med 1994; 35: 1179-84.
173. Ballinger JR, Hua HA, Berry BW, et al. 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16: 253-7.
174. Galski H, Sullivan M, Willingham MC, et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol Cell Biol 1989; 9: 4357-63.
175. Mickisch GH, Merlino GT, Galski H, et al. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991; 88: 547-51.
176. Mickisch GH, Licht T, Merlino GT, et al. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 1991; 51: 5417-24.
177. Levêque D, Jehl F. P-Glycoprotein and pharmacokinetics. Anticancer Res 1995; 15: 331-6.
178. Fischer GA, Lum BL, Hausdorff J, et al. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996; 32A: 1082-8.
179. Horton JK, Thimmaiah KN, Houghton JA, et al. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 1989; 38: 1727-36.
180. Hyafil F, Vergely C, Du Vignaud P, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-602.
181. Colombo T, Zucchetti M D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubincin in mice and rats. J Pharmacol Exp Ther 1994; 269: 22-7.
182. Gonzalez O, Colombo T, De Fusco M, et al. Changes in doxorubicin distribution and toxocity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 1995; 36: 335-40.
183. Arvelo F, Poupon MF, Bichat F, et al. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Eur J Cancer 1995; 31A: 1862-8.
184. Keller RP, Altermatt HJ, Donatsch P, et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992; 51: 433-8.
185. Desrayaud S, Guntz P, Scherrmann J-M, et al. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 1997; 61: 153-63.
186. van Asperen J, Schinkel AH, Beijnen JH, et al. Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice. J Natl Cancer Inst 1996; 88: 994-9.
187. Leu B-L, Huang J-d. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995; 35: 432-6.
188. Speeg KV, Maldonado AL, Liaci J, et al. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology 1992; 15: 899-903.
189. Ellis AG, Crinis NA Webster LK. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 1996; 38: 81-7.
190. Genne P, Duchamp O, Solary E, et al. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anti-Cancer Drug Design 1995; 10: 103-18.
191. Genne P, Coudert B, Pelletier H, et al. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer Res 1989; 9: 1655-60.
192. Lemaire M, Bruelisauer A, Guntz P, et al. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 1996; 38: 481-6.
193. Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996; 18: 350-6.
194. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72.
195. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
196. Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer 1996; 32A: 991-1001.
197. Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991; 83: 105-10.
198. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 1983; 67: 889-94.
199. Cros S, Guilbaud N, Berlion M, et al. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol 1992; 30: 491-4.
200. Loor F, Boesch D, Gavériaux C, et al. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Br J Cancer 1992; 65: 11-8.
201. Watanabe T, Naito M, Oh-hara T, et al. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Jpn J Cancer Res 1996; 87: 184-93.
202. Bright JM, Buss DD. Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs. J Natl Cancer Inst 1990; 82: 963-4.
203. Sridhar R, Dwivedi C, Anderson J, et al. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 1992; 84: 1653-60.
204. van de Vrie W, Jonker AM, Marquet RL, et al. The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J Cancer Res Clin Oncol 1994; 120: 533-8.
205. Froidevaux S, Loor F. Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833. Int J Cancer 1994; 59: 133-40.
206. Tsuruo T, Yusa K, Sudo Y, et al. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Cancer Res 1989; 49: 5537-42.
207. Ohkawa K, Hatano T, Yamada K, et al. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 1993; 53: 4238-42.
208. Mickisch GH, Rahman A, Pastan I, et al. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 1992; 84: 804-5.
209. Tsuruo T, Hamada H, Sato S, et al. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 1989; 80: 627-31.
210. Rittmann-Grauer LS, Yong MA, Sanders V, et al. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 1992; 52: 1810-6.
211. Mickisch GH, Pai LH, Gottesman MM, et al. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res 1992; 52: 4427-32.
212. Fogler WE, Pearson JW, Volker K, et al. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst 1995; 87: 94-104.
213. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785-9.
214. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA. 1992; 89: 5824-8.
215. r 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res 1989; 49: 3209-14.
216. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99-103.
217. Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992; 89: 9676-80.
218. Baudard M, Pastan I Gottesman MM. Transfer of the MDR1 gene into haematopoietic cells. Eur J Cancer 1996; 32A: 1019-23.
219. Bellamy WT. Prediction of response to drug therapy of cancer. Drugs 1992; 44: 690-708.
220. Weisenthal LM. Antineoplastic drug screening belongs in the laboratory, not in the clinic. J Natl Cancer Inst 1992; 84: 466-9.
221. Martin DS, Balis ME, Fisher B, et al. Role of murine tumor models in cancer treatment research. Cancer Res 1986; 46: 2189-92.
222. van der Heyden S, Gheuens E, van de Vrie W, et al. 5′-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related to P-gp 170 expression. Jpn J Cancer Res 1994; 85: 13-6.
223. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255-9.
224. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-60.
225. Verweij J, Herweijer H, Oosterom R, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991; 64: 361-4.
226. Rodenburg CJ, Nooter K, Herweijer H, et al. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991; 2: 305-6.
227. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363-82.
228. Ferry DR, Traunecker H Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996; 32A: 1070-81.
229. Sonneveld P. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer 1996; 32A: 1062-9.
230. VoIm M, Bak M, Efferth T, et al. Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins. Anticancer Res 1988; 8: 1169-78.
231. Slater LM, Sweet P, Stupecky M, et al. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 1986; 54: 235-8.
232. Formelli F, Cleris L Carsana R. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemother Pharmacol 1988; 21: 329-36.
233. Capranico G, De Isabella P, Castelli C, et al. P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines. Br J Cancer 1989; 59: 682-5.
234. Chauffert B, Martin M, Hammann A, et al. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 1986; 46: 825-30.
235. Mattern J, Bak M Volm M. Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice. Anticancer Res 1990; 10: 177-80.